0838 GMT - Novo Nordisk's initial 2025 outlook is just ahead of Jefferies's expectations. But given a higher starting point and stronger currency effects it suggests up to 6% sales and 10% EBIT consensus upgrades, analysts at the bank write. Novo Nordisk's fourth-quarter sales beat expectations by 5%, mostly on positive U.S. gross-to-net adjustments--the discount offered between the list price and the actual net sales price--for its insulins. Sales of Wegovy were shy of expectations while Ozempic and Rybelsus were in line. A better gross margin, higher research and development costs but less selling and distribution spend helped EBIT beat by 9% and EPS by 6%. The stock will likely tick higher initially but could then fade, Jefferies says. Shares trade 4.2% higher at 617.20 Danish kroner. (dominic.chopping@wsj.com)
(END) Dow Jones Newswires
February 05, 2025 03:38 ET (08:38 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.